Global Information
회사소개 | 문의 | 비교리스트

전이성 신세포암(mRCC) 역학 및 시장 예측(2030년) : 1차 조사(KOL 인사이트) - 마켓 인텔리전스

Metastatic Renal Cell Carcinoma (mRCC) | Primary Research (KOL´s Insight) | Market Intelligence | Epidemiology & Market Forecast - 2030

리서치사 Mellalta Meets LLP
발행일 2021년 11월 상품코드 1043373
페이지 정보 영문 293 Pages 배송안내
가격
US $ 6,500 ₩ 8,561,000 PDF (Single User License)
US $ 9,750 ₩ 12,841,000 PDF (2 - 3 User License)
US $ 13,000 ₩ 17,122,000 PDF (Site License - Up to 10 Users)
US $ 19,500 ₩ 25,683,000 PDF (Enterprise License)


전이성 신세포암(mRCC) 역학 및 시장 예측(2030년) : 1차 조사(KOL 인사이트) - 마켓 인텔리전스 Metastatic Renal Cell Carcinoma (mRCC) | Primary Research (KOL´s Insight) | Market Intelligence | Epidemiology & Market Forecast - 2030
발행일 : 2021년 11월 페이지 정보 : 영문 293 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

G7 국가의 전이성 신세포암(mRCC) 시장은 7.5%의 연평균 복합 성장률(CAGR)로 성장하여 2030년에 79억 달러에 이를 것으로 예측됩니다. 시장 성장 주요인으로는 신흥 의약품의 채용을 들 수 있습니다.

현재 전이성 신세포암(mRCC)의 1차 치료 및 2차 치료에는 티로신키나아제 저해제(TKI)나 항VEGF 항체가 널리 이용되고 있습니다. 그러나, 조기진단과 치료 옵션에 대한 미충족 요구가 남아 있습니다. 개발 중인 신약은 mRCC 환자의 옵션을 확대하고, mRCC 치료의 현재 미충족 요구에 대응할 가능성이 높을 것으로 예상되어 향후 시장 경쟁이 촉진되어 예산 지속성에 기여함 것과 동시에 생물학적 제제에 대한 환자 접근성이 향상될 것으로 예측됩니다.

전이성 신세포암(mRCC: Metastatic Renal Cell Carcinoma)에 대해 조사했으며, 현재의 시장 동향, G7 국가의 확진자 현황과 예측, 시장 기회, 경쟁 제품, KOL(Key Opinion Leader) 인사이트 등의 정보를 제공합니다.

샘플

목차

  • 개요
  • 전이성 신세포암(mRCC) 질환의 배경
    • 신세포암(RCC)의 정의
    • 증상과 원인
    • 병인
    • 단계
    • 분류
  • 전이성 신세포암(mRCC) 진단
    • 진단과 진단 가이드라인
    • 바이오마커
    • 과제
  • 역학과 환자 집단
    • 주요 조사 결과
    • 조사 방법과 정보원
    • 전이성 신세포암(mRCC)의 역학 및 모델 파라미터의 주요 정보원
      • 미국
        • 신세포암(RCC)을 동반한 미국의 확진자수
        • 전이성 신세포암(mRCC)을 동반한 확진자수
        • 일련의 치료법별 전이성 신세포암(mRCC) 치료 증례
      • 독일
      • 프랑스
      • 이탈리아
      • 스페인
      • 영국
      • 일본
  • 현재의 치료법과 의료 행위
  • 전이성 신세포암(mRCC) - 치료 연구
  • 미충족 요구
  • 전이성 신세포암(mRCC) - 출시 의약품
  • 새로운 치료법
  • 제품 분석
    • Phase III
      • Belzutifan(Merck/Peloton Therapeutics)
      • Dovitinib(Allarity Therapeutics)
      • Savolitinib(Astrazeneca)
      • Bempegaldesleukin(Bristol-Myers Squibb/Nektar Therapeutics)
      • Atezolizumab(Hoffmann-La Roche/Exelixis)
      • Abexinostat(Xynomic Pharmaceuticals)
    • Phase II
      • PT2385(Kolon Life Science)
      • Sitravatinib(Mirati Therapeutics)
      • Crizotinib(Pfizer)
      • TLX250(Telix Pharmaceuticals)
      • ALT-803(NantWorks/ImmunityBio)
    • Phase I/II
      • AVB-500(Aravive)
  • 전이성 신세포암(mRCC) - 가격과 상환
  • 향후의 치료 패러다임
    • 전이성 신세포암(상황) 경쟁사 상황과 예상되는 승인
    • 향후의 치료 알고리즘과 경쟁사의 포지셔닝
    • 새로운 치료를 위한 중요 데이터 요약
  • 현재 및 새로운 치료법의 연간 비용
  • 시장 전망
    • 주요 조사 결과
    • 2030년까지 국가별 시장 예측
      • 주요 의약품 시장에서의 전이성 신세포암(mRCC) 치료용 약제 판매(2017-2030년)
      • 전이성 신세포암(mRCC) 요법 및 약제별 환자 점유율
  • 국가별 시장 예측
    • 미국
      • 전이성 신세포암(mRCC) 시장(2020-2030, 금액)
      • 치료법별 : 전이성 신세포암(mRCC) 시장(2020-2030, 금액)
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
    • 일본
  • 시장 성장 촉진요인 및 억제요인
LSH 22.01.25

Currently, tyrosine kinase inhibitors (TKIs) and anti-VEGF antibodies are widely used in first- and second-line treatments for mRCC. Despite the current treatments, there remains the unmet need for early diagnosis and treatment options. Emerging drugs in development like Dovitinib (Allarity Therapeutics) and Savolitinib/ AZD6094 (Astrazeneca), and others will expand the first-line and second-line settings for patients with mRCC and likely to address the current unmet needs for the treatment of mRCC. The upcoming treatment options for mRCC can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.

Renal cell carcinoma (RCC) is a type of kidney cancer which originates within the renal cortex and are responsible for 80% to 85% of all primary renal neoplasms. It is the most common form of kidney cancer found in adults. RCC metastasizes in approximately 20-30% of the cases. According to National Cancer Institute, Metastatic renal cell carcinoma (mRCC) is a heterogeneous disease with wide variations in its clinical presentation, natural history, and response to therapy. The most common sites for metastases of RCC are the lungs, bones, liver, and brain. The recurrence of RCC after initial care is relatively high and certain subtypes such as clear cell RCC are more likely to metastasize. A more recent discovery with new immune checkpoint inhibitors heralded a further paradigm shift from TKI monotherapy to immunotherapy-based combinations.

SAMPLE VIEW

Metastatic Renal cell carcinoma (mRCC)- Epidemiology

Renal Cell Carcinoma diagnosis majorly depends on abdominal imaging or upon presentation of invasive disease at common metastatic sites, such as the lung, bone, and liver. Computerized tomography (CT) remains the gold standard for the diagnosis of Renal cell carcinoma (RCC). Abdominal ultrasonography (USG), MRI, blood test and urine analysis are common diagnostic tools being used for the diagnosis. Core biopsy and pathological examination are performed to confirm the diagnosis in case of renal cell carcinoma identified in both kidney and at distant metastatic sites. More than 50% of patients with renal cell carcinoma are asymptomatic and diagnosed incidentally during thoracoabdominal imaging ordered for unrelated issues.

Despite the availability of several optimal imaging strategies and guidelines, the diagnosis of recurrent and mRCC is still a challenge which is generally confounded by various factors, such as the ability of RCC to metastasize to virtually any part of the human body, atypical patterns of manifestation, and limitations in technique.

RCC occurs mostly in adults and often in men ages 50 to 70. The incidence of RCC varies with the highest rates observed in the North America. In the United States, there are approximately 63,000 new cases and almost 14,000 deaths each year. In the United States, incidence rates of RCC have been on the rise through the mid-2000s.

SAMPLE VIEW

Metastatic Renal cell carcinoma (mRCC)- Current Market Size & Forecast Trends

The renal cell carcinoma market has witnessed a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical), Keytruda (Merck & Co.) plus Inlyta (Pfizer), and Bavencio (Pfizer / Merck KGaA) plus Inlyta, are revolutionizing the treatment of advanced disease. The recent approval and uptake of the Opdivoplus Cabometyx (Exelixis / Ipsen) and axitinib plus pembrolizumab combination will also drive fierce competition in this setting. Multiple immune checkpoint inhibitors are also anticipated to enter the early-stage setting over the forecast period. Additionally, the anticipated entry of other agents such as bempegaldesleukin (NektarTherapeutics) and belzutifan (Merck & Co.) will further diversify treatment options and create a highly competitive and dynamic market.

The current treatment market has long been dominated by targeted treatments, including mTOR and angiogenesis inhibitors. However, the introduction of immune checkpoint inhibitors has diversified treatment options and the treatment landscape for renal cell carcinoma market is rapidly moving toward combination combinatorial approaches. The introduction of diagnostic companions could offer the possibility of providing better outcomes and reducing the cost-burden of patients that are less likely to respond to the therapy.

Metastatic Renal cell Carcinoma (mRCC) is expected to see a high growth during our forecast period. The market in the G7 countries is expected to reach USD 7.9 billion in 2030 with a CAGR of 7.5%. Primary drivers of this growth will be the uptake of the emerging drugs i.e., Belzutifan (Merck/Peloton Therapeutics), Bempegaldesleukin (Bristol-Myers Squibb/Nektar Therapeutics), and others.

SAMPLE VIEW

Report Highlights:

  • Metastatic Renal cell carcinoma (mRCC)- Current Market Trends
  • Metastatic Renal cell carcinoma (mRCC)- Current & Forecasted Cases across the G7 Countries
  • Metastatic Renal cell carcinoma (mRCC)- Market Opportunities and Sales Potential for Agents
  • Metastatic Renal cell carcinoma (mRCC)- Patient-based Market Forecast to 2030
  • Metastatic Renal cell carcinoma (mRCC)- Untapped Business Opportunities
  • Metastatic Renal cell carcinoma (mRCC)- Product Positioning Vis-a-vis Competitors' Products
  • Metastatic Renal cell carcinoma (mRCC)- KOLs Insight

Table of Contents

  • Executive Summary
    • Key Findings
  • Metastatic Renal cell carcinoma (mRCC) Disease Background
    • Renal Cell Carcinoma (RCC) Definition
    • Symptoms and Causes
    • Pathogenesis
    • Stages
    • Classification
  • Metastatic Renal cell carcinoma (mRCC) Diagnosis
    • Diagnosis & Diagnostic Guidelines
    • Biomarkers
    • Challenges
  • Epidemiology and Patient Populations
    • Key Findings
    • Methods and data Sources
      • Country Specific Incident Populations with Renal Cell Carcinoma (RCC) (US, Germany, France, Italy, Spain, UK, and Japan)
      • Country Specific Incident Population with Metastatic Renal Cell Carcinoma (mRCC)
      • Country Specific Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
    • Key Sources for Metastatic Renal cell carcinoma (mRCC) Epidemiology and Model Parameters
      • United States
        • United States Incident Populations with Renal Cell Carcinoma (RCC)
        • United States Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
        • United States Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
      • Germany
        • Germany Incident Populations with Renal Cell Carcinoma (RCC)
        • Germany Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
        • Germany Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
      • France
        • France Incident Populations with Renal Cell Carcinoma (RCC)
        • France Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
        • France Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
      • Italy
        • Italy Incident Populations with Renal Cell Carcinoma (RCC)
        • Italy Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
        • Italy Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
      • Spain
        • Spain Incident Populations with Renal Cell Carcinoma (RCC)
        • Spain Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
        • Spain Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
      • United Kingdom
        • United Kingdom Incident Populations with Renal Cell Carcinoma (RCC)
        • United Kingdom Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
        • United Kingdom Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
      • Japan
        • Japan Incident Populations with Renal Cell Carcinoma (RCC)
        • Japan Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
        • Japan Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
  • Current Therapies and Medical Practice
    • Treatments & Medical Practices
    • NCCN Treatment Guidelines
    • First- Line Therapy for Clear Cell Histology as per the NCCN Guidelines
    • Subsequent Therapy for Clear Cell Histology
    • Systemic Therapy for Non- Clear Cell Histology
    • KOLs Opinion on Current Treatment Option
  • Metastatic Renal cell carcinoma (mRCC)- Treatment Studies
    • Treatment patterns of Metastatic Renal cell carcinoma by Line of Therapy: United States
    • Trends in 1 L Treatment Initiation for Metastatic Renal cell carcinoma: United States
    • Treatment patterns of Metastatic Renal cell carcinoma by Line of Therapy: United Kingdom
    • Treatment Patterns in Patients with Metastatic Renal cell carcinoma: Germany
    • Treatment Costs of Patients with Metastatic Renal cell carcinoma: Italy
    • Treatment Costs of Patients with Metastatic Renal cell carcinoma : France
    • In-Hospital Economic Burden of Metastatic Renal Cell Carcinoma: France
    • Treatment Patterns in Patients with Metastatic Renal cell carcinoma: Japan
  • Unmet Needs
  • Metastatic Renal cell carcinoma (mRCC)- Marketed Drug Chapters
    • Treatment Landscape of mRCC
    • Key trials for Renal Cell carcinoma
    • Clinical data comparisons in 1L and 2L settings
    • RCC treatment rankings based on efficacy and safety
    • Product Profile
    • Clinical Trial Analysis
  • Emerging Therapies
    • Pipeline Overview
    • Therapeutic Developments Pipeline for Metastatic Renal cell carcinoma (mRCC)
      • Product Analysis
      • Phase III
        • Belzutifan (Merck/Peloton Therapeutics)
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
        • Dovitinib (Allarity Therapeutics)
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
        • Savolitinib (Astrazeneca)
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
        • Bempegaldesleukin (Bristol-Myers Squibb/Nektar Therapeutics)
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
        • Atezolizumab (Hoffmann-La Roche/Exelixis)
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
        • Abexinostat (Xynomic Pharmaceuticals)
          • Product Profile
          • Clinical Development
          • Sales & Market Opportunity by 2030
      • Phase II
        • PT2385 (Kolon Life Science)
          • Product Profile
          • Clinical Development
        • Sitravatinib (Mirati Therapeutics)
          • Product Profile
          • Clinical Development
        • Crizotinib (Pfizer)
          • Product Profile
          • Clinical Development
        • TLX250 (Telix Pharmaceuticals)
          • Product Profile
          • Clinical Development
  • ALT-803 (NantWorks/ImmunityBio)
    • Product Profile
    • Clinical Development
  • Phase I/II
    • AVB-500 (Aravive)
      • Product Profile
      • Clinical Development
  • Metastatic Renal cell carcinoma (mRCC)- Pricing & Reimbursement
  • Future Treatment Paradigm
    • Metastatic Renal cell carcinoma (mRCC) Competitor Landscape and Approvals Anticipated
    • Future Treatment Algorithms and Competitor Positioning
    • Key Data Summary for Emerging Treatment
  • Annual Cost of Current & Emerging Therapies
  • Market Outlook
    • Key Findings
    • Country Specific Market Forecast to 2030
      • Sales of Drugs to Treat Metastatic Renal cell carcinoma (mRCC) in the Major Pharmaceutical Markets, 2017-2030
      • Patient Share of Metastatic Renal cell carcinoma (mRCC) Therapies and by Drug
  • Market Forecast by Country
    • United States
      • United States Market for Metastatic Renal cell carcinoma (mRCC) 2020-2030 (USD Million)
      • United States Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2020-2030 (USD Million)
    • Germany
      • Germany Market for Metastatic Renal cell carcinoma (mRCC) 2020-2030 (USD Million)
      • Germany Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2020-2030 (USD Million)
    • France
      • France Market for Metastatic Renal cell carcinoma (mRCC) 2020-2030 (USD Million)
      • France Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2020-2030 (USD Million)
    • Italy
      • Italy Market for Metastatic Renal cell carcinoma (mRCC) 2020-2030 (USD Million)
      • Italy Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2020-2030 (USD Million)
    • Spain
      • Spain Market for Metastatic Renal cell carcinoma (mRCC) 2020-2030 (USD Million)
      • Spain Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2020-2030 (USD Million)
    • United Kingdom
      • United Kingdom Market for Metastatic Renal cell carcinoma (mRCC) 2020-2030 (USD Million)
      • United Kingdom Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2020-2030 (USD Million)
    • Japan
      • Japan Market for Metastatic Renal cell carcinoma (mRCC) 2020-2030 (USD Million)
      • Japan Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2020-2030 (USD Million)
  • Market Drivers and Constraints
    • What Factors Are Driving the Market for Metastatic Renal cell carcinoma (mRCC)?
    • What Factors Are Constraining the Market for Metastatic Renal cell carcinoma (mRCC)?
Back to Top
전화 문의
F A Q